Active Ingredient(s): Aducanumab-avwa
FDA Approved: * June 7, 2021
Pharm Company: * BIOGEN INC
Category: Alzheimers / Dementia

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Aduhelm Overview

Aducanumab, sold under the brand name Aduhelm, is a medication designed to treat Alzheimer's disease (AD).[1][2] It is an amyloid beta-directed monoclonal antibody[1][2] that targets aggregated forms of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.[3][4] Aducanumab was approved for medical use in the United States by the Food and Drug Administr...

Read more Aduhelm Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Aduhelm Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 170mg/1.7ml (100mg/ml), 300mg/3ml (100mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Aduhelm: (2 results)

Sorted by National Drug Code
  • 64406-101 Aduhelm 100 mg/ml Intravenous Injection, Solution by Biogen Inc.
  • 64406-102 Aduhelm 100 mg/ml Intravenous Injection, Solution by Biogen Inc.

Other drugs which contain Aducanumab-avwa or a similar ingredient: (1 result)